METHOD FOR PREDICTION OF DEVELOPMENT OF LIPID DISTRESS SYNDROME IN CHRONIC VIRAL HEPATITIS C Russian patent published in 2019 - IPC G01N33/50 G01N33/68 G01N33/92 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to infectious diseases and hepatology, and aims at predicting development of lipid distress syndrome in chronic viral hepatitis C in the absence of antiviral therapy. Method is realized by determining in a patient with chronic hepatitis C following laboratory blood values: concentration of low-density lipoprotein cholesterol, lipoprotein (a), alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, homocysteine, interleukin 4 and thymol test value. Values of two classification functions are calculated by formulas: KF₁ = 146.232x₁ + 0.488x₂ + 0.110x₃ – 0.041x₄ + 0.133x₅ + 4.468x₆ + 4.182x₇ + 43.587x₈ – 565.556; KF₂ = 141.800x₁ + 0.671x₂ + 0.135x₃ – 0.009x₄ + 0.168x₅ + 4.873x₆ + 4.584x₇+ 44.909x₈ – 586.213, where KF₁ – value of classification function of absence of lipid distress syndrome; KF₂ is a function of classifying the development of lipid distress syndrome; x₁ is concentration of low-density lipoprotein cholesterol, mmol/l; x₂ is concentration of lipoprotein (a), mg/dL; x₃ is the alanine aminotransferase concentration, Units/l; x₄ is concentration of aspartate aminotransferase, Unit/l; x₅ is concentration of alkaline phosphatase, Units/l; x₆ – thymol sample, Unit; x₇ is homocysteine concentration, mmol/l; x₈ – concentration of interleukin 4, pg/ml; 565.556 and 586.213 are constants of classification functions obtained by discriminant analysis; 146.232; 0.488; 0.110; – 0.041; 0.133; 4.468; 4.182; 43.587; 141.800; 0.671; 0.135; – 0.009; 0.168; 4.873; 4.584 and 44.909 – coefficients of the discriminant function obtained by discriminant analysis. Determining the classification function with the highest value. If this value KF₁, then absence is determined, and if this value KF₂, then it means development of lipid distress syndrome for next 7 years of life without antiviral therapy.

EFFECT: using the invention enables more accurate prediction of the development of lipid distress syndrome in the patients with chronic viral hepatitis C in the absence of antiviral therapy with an increase in the sensitivity and prognostic value of the negative prediction result to 100 %.

1 cl, 2 ex